TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In the TRIUMPH-4 trial, people with obesity and knee osteoarthritis who received investigational retatrutide reported larger reductions in pain and disability than those receiving placebo over 68 weeks. They also lost more than one-quarter of their body weight on average, while withdrawals and serious adverse events were more common in the drug groups. The results do not establish that retatrutide slows or reverses joint damage.
An investigational drug called retatrutide reduced knee osteoarthritis pain and disability in a 68-week trial of people with obesity, while participants also lost more than one-quarter of their body weight. The TRIUMPH-4 findings, reported at the American College of Rheumatology annual meeting and published in the New England Journal of Medicine, compare two weekly doses with placebo; they do not show that the drug prevents or reverses joint damage.
The trial randomized 445 adults with obesity and knee osteoarthritis to weekly injections of placebo, 9 milligrams of retatrutide or 12 milligrams. Participants had a mean starting body mass index of 40.4 and weighed an average of 113 kilograms. All groups also received individualized dietary counseling and encouragement to do at least 150 minutes of physical activity per week.
At week 68, mean scores on the WOMAC pain scale had fallen by 4.48 points with 9 mg and 4.41 points with 12 mg, compared with a 2.43-point decline with placebo. WOMAC scores also showed greater improvement in physical function: 4.14 and 4.20 points in the two retatrutide groups, respectively, versus 2.06 points with placebo. About 70% of participants in each drug group achieved a 70% reduction in pain scores, compared with 26% in the placebo group.
Weight loss increased through the study period, without an obvious plateau by week 68, the report said. Some participants stopped taking part because they considered their weight loss excessive. Adverse events also led more people to withdraw from the retatrutide groups: about 13% on 9 mg and 18% on 12 mg, versus 4% on placebo. Serious adverse events were reported in about 10% of each drug group and 2% of the placebo group. Gastrointestinal problems were the most common adverse events described in the report.
Pain Relief and Weight Loss
The results add to research on whether substantial weight reduction can ease osteoarthritis symptoms in people with obesity. Knee pain can limit movement and daily activities; the trial’s reported improvements in both pain and physical function may be relevant to patients who have symptoms alongside excess weight. The comparison with placebo is meaningful, though the placebo group also received diet and activity support and improved over the study.
Retatrutide is an investigational drug that acts on three receptor pathways: GLP-1, GIP and glucagon. Its reported weight loss was substantial, but the trial does not establish how much of the pain improvement came from reduced mechanical load on the knee, possible changes in inflammation, or other effects. Nor does symptomatic improvement show that the underlying joint disease has changed.
The adverse-event and withdrawal figures matter alongside the benefits. They indicate that the results are not simply a measure of pain relief: tolerability, the extent of weight loss and the balance of risks and benefits will need careful evaluation. Retatrutide remains investigational, and these findings do not make it an established osteoarthritis treatment.
Products Worth Considering
Therabody Theragun Relief Massage Gun, 3-Speed, Navy
Bowflex SelectTech 840 Adjustable Kettlebell
Hyperice Venom 2 Heated Vibration Back Wrap
As an affiliate, we earn on qualifying purchases.
How TRIUMPH-4 Fits In
TRIUMPH-4 follows the earlier TRIUMPH-1 study, which was also discussed in the simultaneous New England Journal of Medicine publication. The trial focused on people with both obesity and knee osteoarthritis, rather than people with osteoarthritis across all body types. Participants came from the United States, Canada, Mexico, Australia and Spain; 64% had grade 3 osteoarthritis on the Kellgren-Lawrence scale, indicating substantial joint changes.
Weight loss is already emphasized in osteoarthritis care, and the American College of Rheumatology had recently released updated management guidelines giving it greater emphasis, according to the report. Researchers have also discussed “metabolic osteoarthritis” as a possible way to distinguish disease linked to metabolic factors from osteoarthritis associated with injury or gradual joint wear. The TRIUMPH-4 results may inform that discussion, but they do not by themselves establish a distinct disease category or a mechanism for retatrutide’s effects.
The study authors suggested that less body weight could reduce the load placed on the knee and noted that changes in adipose tissue might affect systemic inflammatory signals. These are proposed explanations, not mechanisms demonstrated by the trial. Retatrutide’s three-target action is also distinct from medicines acting on GLP-1 alone or on GLP-1 and GIP; the study’s placebo comparison does not directly establish superiority over those other drugs.
“Weight reduction leads to decreased loading on the knee, and the level of load reduction appears to be a multiple of the actual weight lost.”
— The TRIUMPH-4 and TRIUMPH-1 authors, as quoted in the MedPage Today report
Mechanism and Joint Outcomes
The results reported here do not establish whether retatrutide changes the structure or progression of osteoarthritis. The study showed improvements in reported pain and function, but symptom relief is not proof of disease modification. It is also unclear how much relief came from weight loss, reduced knee loading, changes in inflammation or other factors.
The report calls for further study of the drug’s effects and notes an unanswered question: whether it might help people with osteoarthritis who are metabolically normal, without leading to unhealthy weight loss. The available account does not provide enough detail to assess every adverse-event type or explain why some participants withdrew. Longer-term outcomes and the balance of benefit and risk beyond 68 weeks also remain unknown.
Further Trials and Safety Data
Researchers have called for further studies into the mechanisms behind pain reduction and whether retatrutide has a disease-modifying effect on osteoarthritis. Follow-up evidence would need to clarify whether improvements persist, how joint outcomes change over time and how the drug’s adverse events compare with its benefits.
For now, TRIUMPH-4 is evidence from a 68-week trial in a particular group: people with obesity and knee osteoarthritis who also received structured lifestyle support. The report does not establish retatrutide as an approved or routine treatment for knee osteoarthritis. Future reporting should track additional trial results, safety findings and any regulatory decisions.
Key Questions
What did the TRIUMPH-4 trial find?
Over 68 weeks, participants with obesity and knee osteoarthritis who received either dose of retatrutide had larger average reductions in WOMAC pain and disability scores than participants receiving placebo. The retatrutide groups also experienced substantial weight loss.
How many people took part?
The study randomized 445 participants to placebo, 9 mg of retatrutide or 12 mg, given as weekly injections. All groups received dietary counseling and physical-activity guidance.
Did the trial show that retatrutide repairs knee damage?
No. The reported results concern pain, physical function and weight. They do not establish that retatrutide repairs joint damage or slows osteoarthritis progression.
What side effects were reported?
Gastrointestinal events were the most common adverse events described. Withdrawal because of adverse events was reported in about 13% of the 9-mg group and 18% of the 12-mg group, compared with 4% of placebo participants; serious adverse events occurred in about 10% of each drug group and 2% of the placebo group.
Is retatrutide an established osteoarthritis treatment?
The source describes retatrutide as investigational. The trial results do not establish it as a routine or approved treatment for knee osteoarthritis.
Source: medpagetoday.com
